AstraZeneca’s Farxiga fails to get U.S. approval for Type-1 diabetes
(Reuters) – British drugmaker AstraZeneca Plc said on Monday the U.S. Food and Drug Administration declined to approve its diabetes treatment, Farxiga, for use as a supplement to insulin in adults with a rare type of the condition.
The company said the regulator issued a complete response letter, declining its application for using the drug in patients with Type-1 diabetes where insulin alone has not been able to control blood sugar levels.
Farxiga is already approved in the United States for use in Type-2 diabetes.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)